Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness

References

• Butler I. Retinopathy following the use of chloroquine and allied substances. Ophthalmologica 1965;149:204–208
   PubMed Web of Science ®Google Scholar
• Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40:1482–1486
   PubMed Web of Science ®Google Scholar
• Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003;110:1321–1326
   PubMed Web of Science ®Google Scholar
• Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991;23:292–296
   PubMed Web of Science ®Google Scholar
• Bernstein HN. Chloroquine ocular toxicity. Surv Ophthalmol 1967;12:415–447
   PubMedGoogle Scholar
• Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992;27:237–239
   PubMed Web of Science ®Google Scholar
• Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine: Clinical implications. Clin Pharmacokinet 1996;30:263–299
   PubMed Web of Science ®Google Scholar
• Rennie IG. Clinically important ocular reactions to systemic drug therapy. Drug Saf 1993;9:196–211
   PubMed Web of Science ®Google Scholar
• Stepien KE, Han DP, Schell J, et al. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. Trans Am Ophthalmol Soc 2009;107:28–33
   PubMedGoogle Scholar
• Mount DL, Patchen LC, Williams SB, Churchill FC. Colorimetric and thin-layer chromatographic methods for field assay of chloroquine and its metabolites in urine. Bull World Health Organ 1987;65:615–623
   PubMed Web of Science ®Google Scholar
• Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692–694
   PubMed Web of Science ®Google Scholar
• Sundelin SP1, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 2002;110:481–489
   PubMed Web of Science ®Google Scholar
• Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol 2004;122:973–981
   PubMed Web of Science ®Google Scholar
• Tzekov RT1, Serrato A, Marmor MF. ERG findings in patients using hydroxychloroquine. Doc Ophthalmol 2004;108:87–97
   PubMed Web of Science ®Google Scholar
• Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine and hydroxychloroquine: a neurophysiologic study. Clin Ophthalmol 2012;6:377–383
   PubMedGoogle Scholar
• Pasadhika S1, Fishman GA, Choi D, Shahidi M. Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. Eye (Lond) 2010;24:756–762
   PubMedGoogle Scholar
• Pasadhika S, Fishman GA. Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. Eye (Lond) 2010;24:340–346
   PubMed Web of Science ®Google Scholar
• Ulviye Y, Betul T, Nur TH, Selda C. Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine. Indian J Ophthalmol 2013;61:168–171
   PubMed Web of Science ®Google Scholar
• Kahn JB, Haberman ID, Reddy S. Spectral-domain optical coherence tomography as a screening technique for chloroquine and hydroxychloroquine retinal toxicity. Ophthalmic Surg Lasers Imaging 2011;42:493–7
   PubMed Web of Science ®Google Scholar
• Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;5:S11–S15
   PubMedGoogle Scholar
• Chen E, Brown DM, Benz MS, et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clin Ophthalmol 2010;4:1151–1158
   PubMedGoogle Scholar
• Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 2007;125:775–780
   PubMed Web of Science ®Google Scholar
• Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 2012;130:461–469
   PubMed Web of Science ®Google Scholar
• Rosenthal AR, Kolb H, Bergsma D, et al. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978;17:1158–1175
   PubMed Web of Science ®Google Scholar
• Lai TY, Chan WM, Li H, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005;140:794–807
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, et al. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415–422
   PubMed Web of Science ®Google Scholar